K1Z0 Stock Overview
A medical technology company, engages in the development of products and solutions for the treatment of chronic migraine and rhinitis in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Chordate Medical Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.65 |
| 52 Week High | SEK 10.00 |
| 52 Week Low | SEK 0.05 |
| Beta | 0.91 |
| 11 Month Change | -41.87% |
| 3 Month Change | -17.75% |
| 1 Year Change | -67.43% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| K1Z0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.6% | 2.4% | 0.8% |
| 1Y | -67.4% | -5.0% | 9.1% |
Return vs Industry: K1Z0 underperformed the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: K1Z0 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| K1Z0 volatility | |
|---|---|
| K1Z0 Average Weekly Movement | 22.1% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: K1Z0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: K1Z0's weekly volatility has decreased from 954% to 22% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 3 | Anders Weilandt | www.chordate.com |
Chordate Medical Holding AB (publ), a medical technology company, engages in the development of products and solutions for the treatment of chronic migraine and rhinitis in Sweden. It offers Ozilia, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The company was founded in 2005 and is based in Kista, Sweden.
Chordate Medical Holding AB (publ) Fundamentals Summary
| K1Z0 fundamental statistics | |
|---|---|
| Market cap | €1.61m |
| Earnings (TTM) | -€2.48m |
| Revenue (TTM) | €261.05k |
6.2x
P/S Ratio-0.6x
P/E RatioIs K1Z0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| K1Z0 income statement (TTM) | |
|---|---|
| Revenue | SEK 3.01m |
| Cost of Revenue | SEK 758.59k |
| Gross Profit | SEK 2.25m |
| Other Expenses | SEK 30.82m |
| Earnings | -SEK 28.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 28, 2025
| Earnings per share (EPS) | -29.14 |
| Gross Margin | 74.78% |
| Net Profit Margin | -949.71% |
| Debt/Equity Ratio | 0% |
How did K1Z0 perform over the long term?
See historical performance and comparison